AngioDynamics Inc. (NASDAQ:ANGO)’s share price reached a new 52-week high during trading on Friday . The stock traded as high as $16.42 and last traded at $16.21, with a volume of 265,976 shares traded. The stock had previously closed at $16.03.

ANGO has been the subject of several research reports. Canaccord Genuity downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $14.50 to $13.00 in a research note on Tuesday, April 5th. Zacks Investment Research upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating in a research note on Monday, May 2nd. Piper Jaffray Cos. initiated coverage on shares of AngioDynamics in a research note on Friday, April 8th. They issued a “neutral” rating and a $12.00 price target for the company. Finally, KeyCorp dropped their price target on shares of AngioDynamics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, April 8th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. AngioDynamics has an average rating of “Hold” and a consensus target price of $14.10.

The stock’s market capitalization is $587.12 million. The company has a 50-day moving average price of $13.73 and a 200 day moving average price of $12.02.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Wednesday, July 13th. The company reported $0.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.03. During the same period in the prior year, the business earned $0.14 EPS. The company had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $88.64 million. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. Analysts expect that AngioDynamics Inc. will post $0.65 EPS for the current year.

In other AngioDynamics news, VP Charles R. Greiner sold 3,508 shares of the stock in a transaction that occurred on Friday, May 6th. The shares were sold at an average price of $12.31, for a total transaction of $43,183.48. Following the transaction, the vice president now owns 20,910 shares of the company’s stock, valued at $257,402.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Stephen A. Trowbridge sold 12,940 shares of the stock in a transaction that occurred on Monday, April 25th. The stock was sold at an average price of $12.30, for a total transaction of $159,162.00. Following the transaction, the senior vice president now directly owns 32,469 shares in the company, valued at approximately $399,368.70. The disclosure for this sale can be found here.

A number of institutional investors recently bought and sold shares of the company. Nationwide Fund Advisors increased its position in AngioDynamics by 252.9% in the fourth quarter. Nationwide Fund Advisors now owns 88,374 shares of the company’s stock worth $1,073,000 after buying an additional 63,332 shares in the last quarter. Morgan Stanley increased its position in AngioDynamics by 6.2% in the fourth quarter. Morgan Stanley now owns 98,634 shares of the company’s stock worth $1,198,000 after buying an additional 5,728 shares in the last quarter. Whitebox Advisors LLC bought a new position in AngioDynamics during the fourth quarter worth $1,384,000. Royce & Associates LLC increased its position in AngioDynamics by 19.0% in the fourth quarter. Royce & Associates LLC now owns 640,801 shares of the company’s stock worth $7,779,000 after buying an additional 102,098 shares in the last quarter. Finally, Lapides Asset Management LLC increased its position in AngioDynamics by 1.2% in the fourth quarter. Lapides Asset Management LLC now owns 700,500 shares of the company’s stock worth $8,504,000 after buying an additional 8,400 shares in the last quarter.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.